July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
The FDA approval provides physicians with a once-daily oral PCSK9 inhibitor option to reduce LDL-C in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia.
A systematic review and meta-analysis presented at the 2026 American College of Cardiology Scientific Session evaluated whether tafamidis was associated with improved survival in patients aged 80 years and...
A new ACC/AHA clinical practice guideline on managing adults with congenital heart disease updates its 2018 recommendations by integrating evidence from 2017 to 2024 and emphasizing specialized...
A phase 2 clinical trial found that ataciguat, a soluble guanylate cyclase activator, may slow aortic valve calcification and help preserve cardiac function in patients with moderate calcific aortic valve...
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
